Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related gene...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1824631 |
| _version_ | 1818935267756605440 |
|---|---|
| author | Wan Qin Jun Zou Yongbiao Huang Chaofan Liu Yalin Kang Hu Han Yang Tang Long Li Bo Liu Weiheng Zhao Xianglin Yuan |
| author_facet | Wan Qin Jun Zou Yongbiao Huang Chaofan Liu Yalin Kang Hu Han Yang Tang Long Li Bo Liu Weiheng Zhao Xianglin Yuan |
| author_sort | Wan Qin |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related genes. However, for lung cancer patients with comorbid IPF, whether pirfenidone has any synergetic effect with immune checkpoint inhibitors has not been investigated. In this study, we showed that pirfenidone monotherapy attenuated tumor growth with an increased T cell inflammatory signature in tumors. Co-administration of pirfenidone with PD-L1 blockades significantly delayed the tumor growth and increased survival, compared with the effect of either treatment alone. Combination therapy promoted gene expression with a unique signature associated with innate and adaptive immune response resulted in the infiltration of immune cells and optimal T cell positioning. Furthermore, we showed a great benefit of combination therapy in alleviating the pulmonary fibrosis and reducing the tumor growth in a tumor-fibrosis model. Our results collectively demonstrated that pirfenidone facilitated antitumor immunity and enhanced the efficacy of PD-L1 blockades. It may act as an adjuvant to immunotherapy in cancer treatment, particularly, in lung cancer patients with preexisting IPF. |
| first_indexed | 2024-12-20T05:17:28Z |
| format | Article |
| id | doaj.art-fd843a04666f45679d6c8ab9ee25a4e5 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-20T05:17:28Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-fd843a04666f45679d6c8ab9ee25a4e52022-12-21T19:52:07ZengTaylor & Francis GroupOncoImmunology2162-402X2020-01-019110.1080/2162402X.2020.18246311824631Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in miceWan Qin0Jun Zou1Yongbiao Huang2Chaofan Liu3Yalin Kang4Hu Han5Yang Tang6Long Li7Bo Liu8Weiheng Zhao9Xianglin Yuan10Tongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyTongji Hospital, Huazhong University of Science and TechnologyIdiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related genes. However, for lung cancer patients with comorbid IPF, whether pirfenidone has any synergetic effect with immune checkpoint inhibitors has not been investigated. In this study, we showed that pirfenidone monotherapy attenuated tumor growth with an increased T cell inflammatory signature in tumors. Co-administration of pirfenidone with PD-L1 blockades significantly delayed the tumor growth and increased survival, compared with the effect of either treatment alone. Combination therapy promoted gene expression with a unique signature associated with innate and adaptive immune response resulted in the infiltration of immune cells and optimal T cell positioning. Furthermore, we showed a great benefit of combination therapy in alleviating the pulmonary fibrosis and reducing the tumor growth in a tumor-fibrosis model. Our results collectively demonstrated that pirfenidone facilitated antitumor immunity and enhanced the efficacy of PD-L1 blockades. It may act as an adjuvant to immunotherapy in cancer treatment, particularly, in lung cancer patients with preexisting IPF.http://dx.doi.org/10.1080/2162402X.2020.1824631lung canceridiopathic pulmonary fibrosispd-l1 blockadesimmune-checkpoint inhibitorspirfenidone |
| spellingShingle | Wan Qin Jun Zou Yongbiao Huang Chaofan Liu Yalin Kang Hu Han Yang Tang Long Li Bo Liu Weiheng Zhao Xianglin Yuan Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice OncoImmunology lung cancer idiopathic pulmonary fibrosis pd-l1 blockades immune-checkpoint inhibitors pirfenidone |
| title | Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice |
| title_full | Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice |
| title_fullStr | Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice |
| title_full_unstemmed | Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice |
| title_short | Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice |
| title_sort | pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of pd l1 blockade in mice |
| topic | lung cancer idiopathic pulmonary fibrosis pd-l1 blockades immune-checkpoint inhibitors pirfenidone |
| url | http://dx.doi.org/10.1080/2162402X.2020.1824631 |
| work_keys_str_mv | AT wanqin pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT junzou pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT yongbiaohuang pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT chaofanliu pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT yalinkang pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT huhan pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT yangtang pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT longli pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT boliu pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT weihengzhao pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice AT xianglinyuan pirfenidonefacilitatesimmuneinfiltrationandenhancestheantitumorefficacyofpdl1blockadeinmice |